aTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease.
The company plans to use forced vital capacity as the primary endpoint, with the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
ATYR•
